Prasugrel (Maleic acid) is primarily used as an antiplatelet agent in the prevention of thrombotic events, particularly in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). It works by inhibiting platelet activation and aggregation, reducing the risk of blood clots that can lead to heart attacks or strokes. This medication is often prescribed in combination with aspirin for dual antiplatelet therapy, offering enhanced protection against cardiovascular events. Its rapid onset of action makes it particularly effective in emergency settings. However, it is not recommended for patients with a history of stroke or transient ischemic attack due to an increased risk of bleeding. Careful patient assessment is essential to balance the benefits of preventing clotting with the potential risks of bleeding complications.